- Home>
- Specialties>
- Cardiology>
- Myocardial Infarction
Search for Myocardial Infarction in Cardiology
Physician-authored summaries on the latest research on myocardial infarction, editorials on myocardial infarction, and perspectives on myocardial infarction - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 776 results - Relevance
- Date
You searched for: myocardial infarction in Cardiology
-
Hospital Strategies for Decreasing AMI Mortality
- May 9, 2012
- Joel M. Gore, MD
- Cardiology
Five specific organizational practices significantly associated with lower risk-standardized mortality rates- Reviewing:
- Bradley EH et al., Ann Intern Med 2012 May 1; 156:618.
-
How Meaningful Are Troponin Elevations After PCI?
Registry findings raise questions about the current threshold for MI.- Reviewing:
- Novack V et al., Arch Intern Med 2012 Mar 26; 172:502. Alpert JS and Jaffe AS., Arch Intern Med 2012 Mar 26; 172:508.
-
Optimal Platelet Inhibition for Primary Percutaneous Coronary Intervention
- April 18, 2012
- Howard C. Herrmann, MD
- Cardiology
In STEMI patients, prasugrel plus a glycoprotein IIb/IIIa inhibitor produced the best physiologic results during the first 24 hours of treatment.- Reviewing:
- Valgimigli M et al., JACC Cardiovasc Interv 2012 Mar; 5:268.
-
Danish Findings Show Neither Benefit nor Harm of HRT After Myocardial Infarction
- April 11, 2012
- JoAnne M. Foody, MD
- Cardiology
However, population-wide observational data are potentially useful for estimating risk in individual patients.
CME Exam- Reviewing:
- Bretler D-M et al., BMJ 2012 Mar 27; 344:e1802.
-
Intracoronary Abciximab or Aspiration Thrombectomy During Primary PCI?
- March 27, 2012
- Howard C. Herrmann, MD
- Cardiology
Abciximab reduced infarct size, whereas aspiration thrombectomy did not; however, the effect was small and highly restricted.- Reviewing:
- Stone GW et al., JAMA 2012 Mar 25;:
-
Recent Trends and Determinants of Declines in Coronary Artery Disease in Europe
- February 29, 2012
- Beat J. Meyer, MD
- Cardiology
Three studies explore how changes in comorbidities, socioeconomics, and demographics relate to remarkably consistent patterns in event rates and case fatality.- Reviewing:
- Schmidt M et al., BMJ 2012 Jan 25; 344:e356. Smolina K et al., BMJ 2012 Jan 25; 344:d8059. Bandosz P et al., BMJ 2012 Jan 25; 344:d8136. Tunstall-Pedoe H., BMJ 2012 Jan 25; 344:d7809.
-
U-Shaped Association Between Potassium Level and Acute-MI Mortality
- February 8, 2012
- Joel M. Gore, MD
- Cardiology
Hypokalemia was associated with increased mortality, but so were serum potassium levels ≥4.5 mEq/L, suggesting that repletion measures should be moderated.- Reviewing:
- Goyal A et al., JAMA 2012 Jan 11; 307:157. Scirica BM and Morrow DA., JAMA 2012 Jan 11; 307:195.
-
Readmission Rates in the U.S. vs. the Rest of the World
- February 1, 2012
- Harlan M. Krumholz, MD, SM
- Cardiology
Trial data suggest that readmission after STEMI is more common — and length of initial hospital stay, shorter — in the U.S. than in other countries; but the picture may be skewed.- Reviewing:
- Kociol RD et al., JAMA 2012 Jan 4; 307:66.
-
Bone Marrow Mononuclear Cell Therapy for Ischemic Myocardial Injury: Later Is Not Better
- November 15, 2011
- Harlan M. Krumholz, MD, SM
- Cardiology
Autologous stem cells transplanted in patients with low LVEFs 2 to 3 weeks after AMI produced no improvement in global or regional function.- Reviewing:
- Traverse JH et al., JAMA 2011 Nov 14;: Hare JM., JAMA 2011 Nov 14;:
-
What If MI Patients Got Their Follow-Up Meds for Free?
- November 14, 2011
- Frederick A. Masoudi, MD, MSPH, FACC, FAHA
- Cardiology
In a cluster-randomized study, improvement in adherence — and in some outcomes — was significant but small.- Reviewing:
- Choudhry NK et al. for the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial., N Engl J Med 2011 Nov 14;: Goldman L and Epstein AM., N Engl J Med 2011 Nov 14;:
-
Once Again, Bivalirudin Alone Bests Heparin plus a GPI Free
- November 13, 2011
- Howard C. Herrmann, MD
- Cardiology
Efficacy was similar and bleeding rates were lower with bivalirudin in patients undergoing percutaneous coronary intervention for myocardial infarction without ST-segment elevation.- Reviewing:
- Kastrati A et al. for the ISAR-REACT 4 Trial Investigators., N Engl J Med 2011 Nov 13;:
-
Clopidogrel for Acute MI: 600 mg Beats 300 mg in a Randomized Trial
- November 9, 2011
- Howard C. Herrmann, MD
- Cardiology
In a randomized study underpowered for clinical endpoints, mean infarct size was significantly smaller with the higher loading dose.- Reviewing:
- Patti G et al., J Am Coll Cardiol 2011 Oct 4; 58:1592.
-
Delays in Treatment for STEMI Increase Risk for Heart Failure
- October 5, 2011
- Joel M. Gore, MD
- Cardiology
Findings from a population-based observational study suggest that reducing time from EMS call to PCI could improve morbidity as well as mortality.- Reviewing:
- Terkelsen CJ et al., Ann Intern Med 2011 Sep 20; 155:361.
-
Enoxaparin Edges Out UFH in Patients with Acute Myocardial Infarction
- September 28, 2011
- Beat J. Meyer, MD
- Cardiology
In a randomized comparison, enoxaparin provided a net clinical benefit in patients undergoing primary percutaneous coronary intervention.- Reviewing:
- Montalescot G et al., Lancet 2011 Aug 20; 378:693.
-
Intra-Aortic Balloon Counterpulsation Before Primary PCI Does Not Reduce Infarct Size Free
- August 30, 2011
- Howard C. Herrmann, MD
- Cardiology
In STEMI patients without cardiogenic shock, a technique to improve hemodynamic function before reperfusion had no beneficial effect.
CME Exam- Reviewing:
- Patel MR et al., JAMA 2011 Aug 29;:
-
Culprit Vessel–Only Intervention Better Than Multivessel Intervention for Acute MI
- August 17, 2011
- Howard C. Herrmann, MD
- Cardiology
Observational data and meta-analysis results support current recommendations to treat only infarct-related lesions during primary percutaneous coronary intervention.
CME Exam- Reviewing:
- Kornowski R et al., J Am Coll Cardiol 2011 Aug 9; 58:704. Vlaar PJ et al., J Am Coll Cardiol 2011 Aug 9; 58:692. Bittl JA., J Am Coll Cardiol 2011 Aug 9; 58:712.
-
Antithrombotic Therapy for Primary PCI: Bivalirudin Looks Like a Winner
- August 3, 2011
- Beat J. Meyer, MD
- Cardiology
According to HORIZONS-AMI, the overall benefits of direct thrombin inhibition are still holding strong at 3 years, but late stent thrombosis remains a concern.- Reviewing:
- Stone GW et al., Lancet 2011 Jun 25; 377:2193. Mukherjee D., Lancet 2011 Jun 25; 377:2154.
-
OAT's (Lack of) Impact on Clinical Practice
- July 27, 2011
- Frederick A. Masoudi, MD, MSPH, FACC, FAHA
- Cardiology
Registry data show that the rate of late PCI on completely occluded arteries did not decline after the OAT findings prompted guideline recommendations against it.- Reviewing:
- Deyell MW et al., Arch Intern Med 2011 Jul 11;: Moscucci M., Arch Intern Med 2011 Jul 11;:
-
Okay to Switch from Heparin to Bivalirudin Before Primary Percutaneous Coronary Intervention
- June 22, 2011
- Howard C. Herrmann, MD
- Cardiology
In patients taking unfractionated heparin at baseline, those who switched did as well as — or better than — those who remained on UFH with an added glycoprotein IIb/IIIa inhibitor.- Reviewing:
- Dangas GD et al. for the HORIZONS-AMI Trial Investigators., J Am Coll Cardiol 2011 Jun 7; 57:2309.
-
Even Short-Term NSAID Use Associated with Cardiovascular Events
- June 8, 2011
- JoAnne M. Foody, MD
- Cardiology
Registry data show adverse effects of both selective cyclooxygenase-2 inhibitors and nonselective agents within the first week of treatment.- Reviewing:
- Schjerning Olsen A-M et al., Circulation 2011 May 24; 123:2226.
Sort by:
Items 1 to 20 of 776 results - Relevance
- Date
